Replies to post #93759 on Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

First reference: Poster conclusion PMX30063(B)not so good against Pseudomonas, and other gm -. March 2014 discussion of superbugs does not mention B. I think B prob would not work against the CRE, as discussed prev, or we would have heard about this potential from the company.

Which is not to say that other drugs in development may not work.

Also note fr first reference(2011 poster) that B not so effective vs Strep pneumoniae(also gm +), which would have been very nice, given how big a problem that bug is.

[MinnieM]

Look at the press release from Jan 27, 2015 for the company comments on Gram-negative infections.

http://cellceutix.com/cellceutix-enthusiastic-about-proposed-budget-increase-to-1-2-billion-to-fight-drug-resistance-bacteria/#sthash.UQCVpfih.dpbs

The Centers for Disease Control and Prevention estimates that antibiotic resistance causes about two million illnesses each year and is responsible for 23,000 deaths in the United States. Perhaps nothing exemplifies how deadly superbugs can be quite like the outbreak of Carbapenem Resistant Enterobacteriaceae (CRE) Klebsiella pneumoniae at the National Institute of Health’s Clinical Center in 2012 that killed 11 people. Last month, Forbes published an article discussing the potential danger of athletes and visitors contracting and spreading drug-resistant infections at the upcoming 2016 Olympics in Rio De Janeiro following the Brazil Health ministry determining water in Guanabara Bay contained multi-drug resistant organisms carrying carbapenem-resistant Klebsiella pneumoniae enzymes.

Cellceutix’s research partners have been awarded $2 million in grants from the National Institute of Health, including a recent grant of $500,000 for research on drug-resistant Gram-negative infections.

Cellceutix believes that with its defensin-mimetic portfolio it has the most advanced class of antibiotics to attack and destroy this and possibly other superbugs. The killing ability of the compound against carbapenem-resistant Klebsiella pneumoniae is astounding. Cellceutix is presently conducting safety testing and subsequently will determine if the drug is to be advanced to clinical trials. The Company continues to work with its collaborators at Fox Chase to develop a novel drug candidate as quickly as possible to be ready for the Rio 2016 Olympics where this may become a serious threat.